Home Cart Sign in  
Chemical Structure| 110026-03-4 Chemical Structure| 110026-03-4

Structure of 110026-03-4

Chemical Structure| 110026-03-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate) prevents apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurodeoxycholic acid sodium hydrate is investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.

Synonyms: Sodium taurodeoxycholate monohydrate; Taurodeoxycholic acid(sodium hydrate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Taurodeoxycholic acid sodium hydrate

CAS No. :110026-03-4
Formula : C26H46NNaO7S
M.W : 539.70
SMILES Code : C[C@]12[C@@H](O)C[C@@]3([C@@]4(C)CC[C@@H](O)C[C@]4(CC[C@]3([C@@]1(CC[C@@]2([C@@H](CCC(NCCS([O-])(=O)=O)=O)C)[H])[H])[H])[H])[H].[H]O[H].[Na+]
Synonyms :
Sodium taurodeoxycholate monohydrate; Taurodeoxycholic acid(sodium hydrate)
MDL No. :MFCD00149238

Safety of Taurodeoxycholic acid sodium hydrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Taurodeoxycholic acid sodium hydrate

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MC3T3-E1 cells 3 µg/l 14 or 21 days To assess osteogenic potential, results showed that Se/TUDCA significantly increased ALP expression and calcified nodule formation J Mater Sci Mater Med. 2024 Oct 15;35(1):64
RAW264.7 macrophages 100 µM 24 hours To evaluate the effect of TUDCA on the intracellular survival of B. pseudomallei in RAW264.7 macrophages, results showed that TUDCA significantly reduced the intracellular survival of B. pseudomallei. BMC Microbiol. 2021 May 4;21(1):137
C2C12 murine myotubes 50 µM 48 hours TDCA increased myotube diameter and prevented dexamethasone-induced atrophy Gut Microbes. 2025 Dec;17(1):2449586
MC3T3-E1 cells 3 µg/l 72 hours To evaluate cell proliferation and differentiation, results showed that Se/TUDCA significantly promoted MC3T3-E1 cell proliferation and osteogenic potential J Mater Sci Mater Med. 2024 Oct 15;35(1):64
CD4+ T cells 100 µM TDCA and 100 mM valine 72 hours To evaluate the effect of TDCA and valine on the interaction between CD4+ T cells and M1 macrophages. Results showed that TDCA and valine significantly reduced the frequencies of CD4+IFN-γ+ and CD4+IL-17A+ T cells. Am J Transplant. 2022 Feb;22(2):402-413
Splenic monocytes 100 µM TDCA and 100 mM valine 96 hours To evaluate the effect of TDCA and valine on LPS-induced M1 macrophage polarization. Results showed that TDCA and valine significantly reduced LPS-induced polarization of F4/80+CD11b+CD11c+ M1 macrophages. Am J Transplant. 2022 Feb;22(2):402-413

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice C26 cancer cachexia model Intraperitoneal injection 10 mg/kg Daily administration until the end of the experiment TDCA improved cholesterol homeostasis and reduced hepatic cholesterol levels but did not prevent muscle atrophy Gut Microbes. 2025 Dec;17(1):2449586
Pigs PRRSV inactivated vaccine immunization model Oral 10 mg/kg 7 days RPP treatment significantly increased the concentrations of PRRSV GP5 protein antibody, IL-2, IL-4, IL-10, and IFN-γ, and optimized gut flora and blood metabolites. Front Immunol. 2024 Jun 26;15:1352018
C57BL/6 mice Melioidosis model Injection 100 μg/g Every 2 days for 10 days To assess the effect of TUDCA on the survival of melioidosis mice, results showed that TUDCA significantly improved the survival rate of mice, reduced bacterial loads and inflammatory responses in the lungs, spleen, and liver. BMC Microbiol. 2021 May 4;21(1):137
C57BL/6J mice High-fat diet-induced non-alcoholic fatty liver disease (NAFLD) model Oral 1000 mg/kg Once daily for 4 weeks To evaluate the therapeutic effects of TUDCA on a high-fat diet-induced NAFLD mouse model. TUDCA significantly attenuated hepatic steatosis, inflammatory responses, obesity, and insulin resistance, improved intestinal barrier function, reduced intestinal fat transport, and modulated gut microbiota composition. Br J Pharmacol. 2018 Feb;175(3):469-484
Rd10 mice, P23H rats, BN rats, etc. Models of RP, DR, RDT, etc. Intraperitoneally, subcutaneously, in eye drops 100-750 mg/kg 1 day to 60 days Protection of retinal function and structure by inhibiting apoptosis, decreasing inflammation, attenuating oxidative stress, etc. Curr Neuropharmacol. 2024;22(8):1374-1390
Mice Laparotomy model Intraperitoneal injection 200 mg/kg Single dose, 30 min before surgery Inhibiting ER stress alleviates NLRP3 inflammasome activation and neuroinflammation, improving postoperative cognitive function CNS Neurosci Ther. 2024 Oct;30(10):e70049
Sprague Dawley (SD) rats Spinal cord injury (SCI) model Oral 200 mg/kg Once daily for 28 days To evaluate the effects of combined TUDCA and BMSC transplantation on functional recovery and tissue regeneration in SCI rats. Results showed that TUDCA significantly accelerated tissue regeneration (assessed by HE, Nissl, MAP2, MBP, TUJ1, and GFAP) and improved functional recovery (assessed by BBB score). These effects were mediated via upregulation of Nrf-2, NQO-1, and HO-1 expression levels. Mol Neurobiol. 2024 Jul;61(7):3753-3768
Wistar albino male rats STZ-induced type 2 diabetes model Intraperitoneal injection 300 mg/kg Once daily for 15 days To evaluate the antidiabetic effects of TUDCA in STZ-induced diabetic rats, results showed TUDCA significantly reduced blood glucose, HbA1c%, and HOMA-IR, increased insulin levels, and improved lipid metabolism, oxidative stress, inflammation, and apoptosis. Int J Mol Sci. 2024 Jun 25;25(13):6922
C57BL/6J male mice 18-month-old aged mice model Intraperitoneal injection 300 mg/kg Once daily for 20 consecutive days To evaluate the effects of TUDCA on glucose-insulin homeostasis in aged mice. Results showed TUDCA improved hyperinsulinemia and glucose homeostasis by enhancing liver insulin-degrading enzyme (IDE) expression and insulin clearance. Sci Rep. 2022 Dec 23;12(1):22273
Sprague Dawley rats Ovariectomized osteoporosis model Local administration 300 μg/30 μL Single dose, maintained for 3 months To evaluate the effect of Se/TUDCA on bone regeneration in osteoporotic rats, results showed that Se/TUDCA significantly promoted bone regeneration and reduced oxidative stress J Mater Sci Mater Med. 2024 Oct 15;35(1):64
C57BL/6j mice Ocular alkali burn model Intraperitoneal injection 400 mg/kg Once daily for 3 days To investigate the effect of TUDCA on inflammation after ocular alkali burn, results showed that TUDCA inhibited inflammation in the cornea and retina and protected retinal ganglion cells. Int J Mol Sci. 2022 Oct 3;23(19):11717
Rats ET B receptor-deficient rats Intraperitoneal injection 400 mg/kg/day Daily for 3 weeks To evaluate the protective effects of TUDCA against high salt diet-induced renal injury. Results showed that TUDCA significantly reduced proteinuria and albuminuria, ameliorated glomerular and proximal tubular damage, and decreased renal cortical cell death and inflammation. Acta Physiol (Oxf). 2019 May;226(1):e13227
C57BL/6 mice Diet-induced obese (DIO) mouse model Intraperitoneal injection TDCA (50 mg/kg) and valine (200 mg/kg) Daily injections until the end of the observation period post-transplantation To evaluate the effect of TDCA and valine on transplant survival in obese mice. Results showed that the combined treatment of TDCA and valine significantly prolonged graft survival in obese mice, reduced the frequencies of CD4+IFN-γ+ and CD8+IFN-γ+ T cells, and increased the frequencies of Tregs and IL-10-producing CD4+ T cells. Am J Transplant. 2022 Feb;22(2):402-413

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.85mL

0.37mL

0.19mL

9.26mL

1.85mL

0.93mL

18.53mL

3.71mL

1.85mL

References

 

Historical Records

Categories